The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. - Wikidata - wikimedia - TriplyDB

The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.

The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.

http://www.wikidata.org/entity/Q36832124

about

Targeted destruction of photosensitive retinal ganglion cells with a saporin conjugate alters the effects of light on mouse circadian rhythms.Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization Porcine sialoadhesin (CD169/Siglec-1) is an endocytic receptor that allows targeted delivery of toxins and antigens to macrophages In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia The influence of Cox-2 and bioactive lipids on hematological cancers.Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia.In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.Acute myeloid leukemia stem cells and CD33-targeted immunotherapy Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts Salvage therapy for relapsed or refractory acute myeloid leukemia Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin Detecting and treating cancer with nanotechnology.Basic and clinical immunology of Siglecs Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.Siglecs as targets for therapy in immune-cell-mediated disease.Structural and conformational features relevant to the anti-tumor activity of calicheamicin γ 1I.The future role of monoclonal antibody therapy in childhood acute leukaemias.New therapeutic approaches to acute myeloid leukemia.Gemtuzumab ozogamicin in acute myeloid leukemia.Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?DNA end-processing enzyme polynucleotide kinase as a potential target in the treatment of cancer.Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice.Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia.Engineering therapeutic monoclonal antibodies.Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.Targeting Leukemia Stem Cells in the Bone Marrow Niche.Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.

P2860

Q21144236-422ECA1C-D38C-4D5D-8ACE-D248757218AD Q28476825-D54EC86C-C879-480F-9129-993096B34D38 Q28477167-4DC4D688-3F0E-4E93-B721-9B9E38C52B96 Q28554677-C5880EF7-25B5-468C-99DC-02DAA6586672 Q33688673-D69CB72C-F680-4877-BEC1-83DAAB9A6D43 Q33944427-0286C96D-B2EF-4139-883C-7C0E3F79CBF0 Q35681332-5033922D-0C93-4C8F-93AB-98CAE6663968 Q35930622-EC645E8F-8EA1-4968-BBBD-6F6F38CDC76D Q36058588-86804329-80F4-4963-A438-F48B2E69FC00 Q36591404-77539FF7-4047-4F19-8885-6E41A2086BC7 Q36612564-74E8EE8F-E975-4C0B-86EF-10BAEB2D3692 Q36932014-9164FAD4-2CCD-4EF6-9425-E9B3D951C070 Q37089855-EA075F00-6CD7-42F4-8219-C8C425D89E57 Q37348437-7DA2AECE-AB16-406E-A1B6-1CC47187F980 Q37381414-0D912772-2322-46E8-968C-FD86F1233F01 Q37440061-80974695-9C42-41D0-9809-51559C5F5203 Q37907992-BF1F0B71-0E20-4C47-8706-C1878C4DC322 Q38033600-A3192785-AC2D-4532-8F2F-6F041184D2C0 Q38090673-2CAC6E60-9DAF-4879-987D-7D3E0567C849 Q38728718-9D01D8C7-BA8B-4689-8DEC-8E4609ECC0AB Q39067366-4C5EBBD3-D1AB-446B-BE88-035C3CCC7996 Q39866360-838F89FC-8AA6-4B44-90FC-057311941A9E Q46120171-EB75F9CA-1324-400A-BDED-197CC54BE79B Q46676396-4C42369C-ECC8-4397-8C79-2E0CD4B0866C Q47820029-E0ED512E-57E9-4447-A899-0AA1F471E838 Q48255324-049C34CF-2389-4AF1-8DA6-7EEA406EAB2A Q52375473-5024A589-1622-48FF-9BF0-BF6FF17A55D7 Q52883093-5E5FF12D-F7ED-4B1C-A6D0-113013D9566D

P2860

The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.

http://www.wikidata.org/entity/Q36832124

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.

@en

type

label

The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.

@en

prefLabel

The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.

@en

P1433

Q36832124-AD261FEA-AF4E-4B34-B6F3-1771C0C177B0

P1476

Q36832124-7CBE6734-BC5A-40CE-8948-CBFBD9D9FFAA

P2093

Q36832124-6329D3B3-9A72-4C3A-BCD5-4257EB263E88

Q36832124-BD76F852-66AC-48FC-B6B4-14D2A8964A02

Q36832124-BDAC084C-CD4D-4703-BCC3-0BF16C25F723

Q36832124-DA79D9A6-09F5-4571-BEBF-7E2C0954618E

Q36832124-DF531263-178D-4ECF-8F97-26AEAD69133D

P2860

Q36832124-0090FCF5-5772-42BA-A556-D0A652119A33

Q36832124-033C3214-38E5-4BC3-B768-4C7C0805B88A

Q36832124-120F67C1-77DB-4B28-8C55-882A2E6234C3

Q36832124-1A46F7D8-8434-46E1-8364-BE0436BD31A5

Q36832124-1D1DA3A3-B968-45C5-BB29-CD2F17AF5C33

Q36832124-24BAB70E-4BE3-48C5-AB9E-B086688DD235

Q36832124-48FCD60C-7B7E-4CE1-A305-20AE9A545E9E

Q36832124-4E2FD1FF-2D0E-4877-9079-B0D049A31509

Q36832124-4E9A275B-0EED-41ED-A690-E3C0AEB8C41B

Q36832124-52F94007-F62E-4AEE-96E0-98FF21116FEB

P2888

Q36832124-73285EBD-176C-4ABB-8F99-804029757815

P304

Q36832124-1EA25813-005F-4DFF-BEDF-77DF3DF216A9

P31

Q36832124-E9737031-BB3A-4D04-8C55-CFF3972E37B8

P356

Q36832124-DABC15F0-1525-4911-9C8C-D3A35B24EEE3

P407

Q36832124-8B868F0D-AA87-499A-AB9B-58953A188AC0

P433

Q36832124-793D65F9-779E-4290-A9D3-B8DA819E92EA

P478

Q36832124-26844E07-EDEC-4BAC-9C0D-470090C1EE26

P577

Q36832124-AD9A9492-0D6B-4A33-9751-278ED6CBC44A

P5875

Q36832124-FE4D1565-3352-49D4-B321-EF51157821F2

P6179

Q36832124-B281DA2B-1998-4339-A1C7-D35013641535

P698

Q36832124-452C7E47-57B5-4A46-AD13-76E8C7342982

P921

Q36832124-312D49EF-057C-4230-8B78-CB5DF2357433

P356

P1433

P1476

The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.

@en

P2093

G Leone

http://www.w3.org/2001/XMLSchema#string

L Fianchi

http://www.w3.org/2001/XMLSchema#string

L Pagano

http://www.w3.org/2001/XMLSchema#string

M Caira

http://www.w3.org/2001/XMLSchema#string

S Rutella

http://www.w3.org/2001/XMLSchema#string

P2860

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas.

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.

Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove.

Treatment of relapsed and refractory acute myelogenous leukemia.

Veno-occlusive disease of the liver.

p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells.

P2888

P304

3679-3690

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1210364

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2007-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6305392

http://www.w3.org/2001/XMLSchema#string

P6179

1006318040

http://www.w3.org/2001/XMLSchema#string

P698

17530021

http://www.w3.org/2001/XMLSchema#string

P921